Accelerated tendon and ligament healing (rodent) [1][2]
Repeated reports of faster and mechanically stronger healing in transected Achilles tendon, quadriceps tendon and medial collateral ligament models, including improved tendon-to-bone healing.
PrecisePep/Peptide Library/BPC-157
Regenerative & Tissue Repair
BPC-157
Body Protection Compound-157 · PL 14736 · Bepecin · pentadecapeptide BPC 157
A 15-amino-acid fragment of a gastric protective protein with an unusually broad pre-clinical healing literature — and an unusually thin human one. The gap between those two facts defines this compound.
00 Overview
BPC-157 has one of the largest pre-clinical literatures of any research peptide and one of the smallest clinical ones. It is a synthetic 15-residue partial sequence of a protein isolated from human gastric juice, developed principally by Sikirić and colleagues in Zagreb, whose group has published a decades-long body of rodent work covering gastrointestinal ulceration, tendon and ligament injury, bone, muscle, nerve, vascular occlusion, and drug and toxin injury.[1][2]
The rodent results are consistent and often striking. They are also, almost without exception, from a single research programme, in rodents, at doses and routes that do not map cleanly onto human subcutaneous use. There is a human record — BPC-157 entered clinical evaluation as PL 14736 for inflammatory bowel disease and was described as safe in that setting — but no adequately powered published human efficacy trial exists for the musculoskeletal indications that drive nearly all real-world interest.[3]
Understanding that asymmetry is the whole job of reading this page. "Study-reported" below almost always means reported in rats. That is not nothing — it is where every drug starts — but it is not a demonstration that the compound repairs a human tendon.
The replication problem
The concentration of BPC-157 evidence in one group's output is the most important methodological caveat attached to this peptide. Independent replication of the headline musculoskeletal findings is limited. This is a known weakness in the literature, not a criticism invented here, and it should scale down confidence in every claim on this page accordingly.
// Mechanism of action
Angiogenesis via VEGFR2. The most consistently reported mechanism is upregulation of VEGF receptor 2 signalling and downstream nitric-oxide production, promoting new vessel formation at injury sites. Improved perfusion is the plausible common denominator behind healing effects across otherwise unrelated tissue types.[2]
Nitric oxide system modulation. A large body of the Zagreb work characterises BPC-157 as interacting with the NO system in both directions — counteracting the effects of NO synthase inhibition and of NO donors — which is offered as an explanation for its reported cytoprotection across vascular, gastrointestinal and neurological insults.[4]
Fibroblast migration and FAK-paxillin signalling. In vitro work in tendon fibroblasts reports increased cell survival, migration and F-actin formation through the FAK-paxillin pathway — a plausible route to the tendon-healing findings.
Growth factor receptor and EGR-1 upregulation. Reported increases in growth hormone receptor expression in tendon fibroblasts and in early growth response-1 gene expression, both of which would sensitise repairing tissue to endogenous anabolic signalling.
Gut barrier and gut–brain axis. The compound's origin is gastric; the earliest and strongest work is on mucosal protection and ulcer healing, with more recent rodent work extending to tight-junction integrity and to gut–brain effects on dopaminergic and serotonergic systems.
01 Reported benefits
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Distant-organ effects from systemic dosing (rodent) [7][8][9]
The rodent literature is not confined to the injection site, and this is one of the more striking things about it. Given intragastrically or intraperitoneally — nowhere near the target tissue — BPC 157 has reported protective effects on liver, kidney and lung after hind-limb ischaemia-reperfusion injury; reversal of multi-organ dysfunction after superior mesenteric artery occlusion, apparently by recruiting collateral vessels around the blockage; and muscle-to-bone reattachment after surgical detachment of the quadriceps, from per-oral dosing. Whatever it is doing in these models, it is doing it systemically rather than as a purely local repair agent.
Gastric and intestinal ulcer healing (rodent) [1][5]
The foundational literature: protection against and healing of gastric lesions from NSAIDs, alcohol, stress and surgery, plus anastomosis and fistula healing across the GI tract.
Human safety signal in inflammatory bowel disease [3]
BPC-157 was developed as PL 14736 and evaluated clinically for inflammatory bowel disease; the compound is repeatedly described in the literature as having been safe in those trials with no reported toxicity. Efficacy in that indication was not established to approval.
Angiogenesis and improved perfusion at injury sites (rodent) [2][4]
Increased VEGFR2 expression, vessel formation and collateral perfusion, including in models of major vessel occlusion.
Protection against NSAID toxicity (rodent) [1]
Counteraction of NSAID-induced gastrointestinal, hepatic and brain lesions in rodents — one of the more frequently replicated findings within the programme.
Nerve and spinal cord injury recovery (rodent) [2]
Reported functional recovery in peripheral nerve transection and spinal cord compression models.
Muscle healing and counteraction of muscle atrophy (rodent) [6]
Reported improvement in crush-injury and denervation muscle models.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Human tendinopathy and chronic soft-tissue injury repair
The single largest reason people use this compound, and the one with no human trial behind it. Rodent tendon healing is a genuine finding; the leap to a human with a six-month rotator-cuff problem is unvalidated.
Leaky gut, IBS and gut-barrier restoration in humans [3][5]
Extrapolated from the mucosal and tight-junction rodent work plus the IBD development history. Mechanistically the most defensible human hypothesis attached to BPC-157, and still a hypothesis.
Improved levothyroxine and trace mineral absorption in hypothyroidism
Extrapolated from the mucosal repair literature. The premise is unusually well grounded — malabsorption genuinely increases levothyroxine requirement, and the T4→T3 deiodinases are selenoenzymes. What is absent is any evidence BPC-157 does this in a human.
Post-surgical recovery acceleration
Follows from the anastomosis and wound-healing models. No human surgical outcome data.
Mood and gut–brain axis effects [2]
Rodent work reports effects on dopaminergic and serotonergic systems and on behavioural models. Human translation is speculative.
Gut symptoms in fibromyalgia via the gut–brain axis
IBS is genuinely and highly comorbid with fibromyalgia, so improving gut symptoms is a plausible quality-of-life gain. The further claim — that this reduces central pain amplification — is a much longer chain, and fibromyalgia is not characterised by the elevated systemic inflammation the argument proposes to lower.
Cytoprotection during high training loads
A generalisation of the "body protection compound" framing to athletic overreaching. Entirely inferential.
Absence of reported tolerance — and what that does and does not mean [2]
A claim circulates that BPC 157 produces no tachyphylaxis and can therefore be run indefinitely without cycling. Be precise about the evidence: no study has tested for tachyphylaxis in either direction. What exists is an absence of reported tolerance in rodent work, and those studies typically run days to weeks — not long enough to detect it even if it occurred. The mechanistic argument offered, that a compound acting across several pathways rather than one receptor is harder to desensitise, is reasonable and untested. Absence of evidence of tolerance is not evidence of absence, and it is not a demonstration that daily use for years is either effective or safe. Continuous dosing is a defensible reading of current evidence. It is not an established one.
Concern: angiogenesis is not selectively beneficial
A compound that promotes new vessel growth promotes it wherever the signal lands. The theoretical implication for occult tumours or proliferative retinopathy is the most important unresolved question about long-term use and has never been formally studied.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Rapid relief of tendon and joint pain
The dominant community report — frequently within one to two weeks, most often for elbow, shoulder, knee and Achilles complaints. Uncontrolled, unblinded, and confounded by the natural history of soft-tissue injury, which is to improve with time and load management.
Resolution of gastrointestinal symptoms
Reflux, gastritis and general gut complaints reported to improve on oral or subcutaneous use. The most mechanistically coherent anecdotal claim for this compound.
Reduced systemic inflammation and improved recovery between sessions
Broadly reported, unmeasured, and near-impossible to separate from training and sleep changes made at the same time.
Local injection near the injury site
Widely practised on the belief that proximity improves outcome. The rodent literature repeatedly reports systemic administration working for remote injuries, which argues the practice may be unnecessary — and localised injection into or near a joint or tendon sheath carries infection and structural risk that systemic subcutaneous injection does not.
Non-response is also reported
A meaningful fraction of community reports describe no effect at all, particularly for chronic degenerative rather than acute inflammatory problems. Under-represented because non-events are under-posted.
02 Adverse effects & risks
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No toxicity reported across the rodent programme [1][2]
The Zagreb literature consistently reports an absence of toxicity, including at high doses and in lethal-dose testing. This is a real finding and it is also the finding most vulnerable to single-programme reporting bias.
Described as safe in human IBD clinical evaluation [3]
The clinical development history as PL 14736 is repeatedly cited as having produced no safety signal. The trials were small and the full data is not readily available in the public literature.
No formal human pharmacokinetic or long-term safety data
There is no published human PK profile, no chronic-dosing safety study, and no long-term follow-up. Absence of reported harm here means absence of investigation, not demonstrated safety.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Pro-angiogenic effects in unwanted tissue
The central theoretical risk. Angiogenesis supports tumour growth and drives proliferative retinopathy. Nobody with an undiagnosed malignancy would know they were feeding it, and no study has looked.
Immunogenicity with repeated administration
Any injected peptide can raise antibodies. Untested here.
Iatrogenic thyrotoxicosis via improved levothyroxine absorption
The direct consequence of the mechanism working. A levothyroxine dose titrated against impaired absorption becomes excessive if absorption improves, producing palpitations, tremor, anxiety and heat intolerance — and, sustained, atrial fibrillation and bone loss. Distinguishable from a peptide side effect only by a thyroid function test.
Fibrosis or excessive scar formation
A compound that accelerates repair signalling could in principle drive disordered repair. Rodent work reports the opposite; the theoretical concern remains unexamined in humans.
Unknown effect on established cardiovascular disease
Vascular and NO-system effects in a healthy rodent are not the same as in an atherosclerotic human. No data.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Injection-site pain, redness and small nodules
The most commonly reported adverse effect, generally mild and self-limiting. More prominent when BPC-157 is co-administered in blends containing GHK-Cu.
Transient fatigue, headache or lightheadedness after injection
Reported inconsistently and often attributed to the vasoactive/NO-related mechanism. Unverified.
Nausea and loose stools with oral use
Reported with oral capsule or "arginate salt" preparations.
Product-purity failures
BPC-157 is one of the most widely counterfeited research peptides precisely because demand is high and the sequence is simple. Under-dosed and mis-sequenced product is a recurring finding in community testing threads.
03 Dosing ranges
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Rodent dosing does not convert cleanly to human use [1][2]
The pre-clinical literature typically uses microgram-per-kilogram to nanogram-per-kilogram ranges by intraperitoneal or intragastric route, often with a remarkable flatness of dose–response across several orders of magnitude. Allometric scaling from these figures to a human subcutaneous dose is not a validated exercise and is the origin of almost every number in circulation.
Clinical development dosing (PL 14736) [3]
The IBD development programme used defined clinical doses; full dosing detail is not consistently available in the accessible literature. This is the only genuinely human-derived dosing reference point that exists.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Route matters more than dose
Given the short systemic half-life and the strong intragastric literature, an argument exists that oral administration is the better-supported route for gut indications and injection for systemic ones. Community practice largely ignores this distinction.
Twice-daily division on half-life grounds
Systemic half-life is short. Splitting a daily amount across two administrations is the standard mechanistic argument for the near-universal community practice of BID dosing.
Continuous rather than cycled use
No receptor-desensitisation mechanism has been identified for BPC-157, which is the basis of the widespread claim that it does not require cycling. Absence of an identified mechanism is not evidence that none exists.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
250–500 mcg once or twice daily
The overwhelmingly dominant community range, giving 250–1000 mcg per day. Almost every protocol in circulation sits inside it.
500 mcg twice daily for acute injury
The "blast" figure reproduced in community injury protocols, typically for four to six weeks before stepping down.
250 mcg daily as maintenance
Long-run low-dose use, frequently reported as continuous for months without cycling.
Oral BPC-157 for gut-specific use
Capsules or arginate-salt preparations at similar microgram figures, on the argument that gut indications do not require systemic exposure. Bioavailability of these preparations is not characterised.
| Community use case | Typical dose | Frequency | Reported duration |
|---|---|---|---|
| Acute injury "blast" | 500 mcg | Twice daily | 4–6 weeks |
| Standard repair | 250–500 mcg | Once daily | 6–8 weeks |
| Maintenance | 250 mcg | Once daily or 5 days/week | Ongoing |
| Gut-focused (oral) | 250–500 mcg | Once or twice daily | 4–8 weeks |
| In KLOW blend | Blend-dependent | Once daily | Per blend cycle |
04 Synergy & interactions
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
No human combination studies exist
There is no trial-grade evidence for BPC-157 in combination with any other peptide. Every entry in the tiers below is inference or community practice.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
What an approved gut peptide actually looks like
Two peptide drugs are licensed for intestinal conditions: teduglutide, a GLP-2 analogue that grows intestinal mucosa in short bowel syndrome, and linaclotide, an orally administered guanylate cyclase-C agonist for IBS with constipation. Neither is a competitor to BPC-157 and neither validates it. They are here as a calibration: teduglutide does what people hope BPC-157 does, it has randomised human evidence for it, and the price of that trophic mechanism is a labelled risk of accelerating neoplastic growth and a mandatory colonoscopy schedule. Growing gut is not a free action.
BPC-157 + TB-500 (the "Wolverine" logic)
The stated rationale is complementary rather than overlapping mechanisms: BPC-157 builds local vasculature and signals fibroblasts; TB-500 mobilises cells systemically through actin regulation. Coherent on paper, never tested as a pair.
BPC-157 + GHK-Cu
Repair scaffolding plus extracellular-matrix remodelling. A secondary practical claim is that BPC-157 reduces the notorious injection-site sting of GHK-Cu; this is a community observation with no pharmacological characterisation.
BPC-157 + KPV
Anti-inflammatory groundwork plus repair signalling — the argument for KLOW over GLOW. The proposition that suppressing NF-κB improves the environment for repair is reasonable and undemonstrated in combination.
BPC-157 alongside GH secretagogues
Rodent work reporting increased growth hormone receptor expression in tendon fibroblasts is the mechanistic hook for pairing BPC-157 with a GH secretagogue. Interesting, and a long way from demonstrated.
BPC-157 with GLP-1 class agents for GI tolerance
Community rationale is that gut-protective effects offset incretin-driven GI adverse effects. No interaction data of any kind.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
BPC-157 + TB-500 as the default injury stack
The most widely used peptide combination in the research community, by a wide margin.
As a component of KLOW and GLOW blends
BPC-157 appears in both of the major repair blends; in KLOW it sits alongside TB-500, GHK-Cu and KPV.
Cycled against KLOW as the "always-on" component
The Gold Standard protocol treats BPC-157 and TB-500 as the two components that never need cycling, rotating the blend around them.
05 Protocols
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
PL 14736 clinical development [3]
The inflammatory bowel disease programme is the only human protocol context for this compound. It did not reach approval.
Standard rodent injury-model design [1][2]
Typical design: induce a defined lesion, administer daily by intraperitoneal or intragastric route, assess healing by functional, biomechanical and histological endpoints at fixed timepoints against a saline control.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Acute phase then maintenance
Higher-frequency dosing during the acute inflammatory and proliferative phases of healing, stepping down for remodelling. Follows standard wound-healing biology rather than any BPC-157-specific data.
Load management is not optional
Tendon remodelling is mechanically driven. Any protocol that pairs a repair peptide with continued aggravating load is working against itself — this is well established in tendinopathy rehabilitation literature independent of any peptide.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Gold Standard Protocol — never cycled
BPC-157 and TB-500 are explicitly named as the two components that do not require cycling, with reports of chronic-issue benefit accumulating around the eight-to-nine month mark. Reproduced as circulated; the timeframe claim has no source.
KLOW → Wolverine rotation
Four vials of KLOW, then two vials of Wolverine blend at 1 mg, then back to KLOW — stated purpose being to reset melanocortin receptor sensitivity and avoid continuous copper exposure.
4–6 week acute injury blast
500 mcg twice daily with TB-500 loading, then step-down. The most common acute-injury schedule in circulation.
05b Condition-specific interest
BPC-157 is the most-discussed compound in this library and is proposed for more conditions than anything else in it. The sections below are ordered by how well grounded the premise is, not by how often the claim is made — and those two orderings are close to inverted.
No approval, no trial
BPC-157 is not approved anywhere. One correction to a claim made almost everywhere, including previously on this page: it is not purely preclinical. Under the development codes PL-10, PLD-116 and PL 14736, a Croatian pharmaceutical company took it through a published phase 1 study by rectal administration in healthy volunteers and a randomised placebo-controlled phase 2 trial of enemas in mild-to-moderate ulcerative colitis, presented in abstract form in 2005. The full results were never published and no product followed. Unpublished results plus abandoned development is a pattern that more often reflects a negative result than a positive one — that is an inference rather than a fact, and it is a more honest summary than either “it has human trials” or “it is rodent-only”. Note also the route: rectal, for colitis. Not subcutaneous, for tendon.
For every condition on this page the evidence is preclinical. The literature behind every entry below is preclinical — overwhelmingly rodent work, much of it from a single research programme in Zagreb spanning three decades. A large body of consistent animal data from one group is a reason to take a compound seriously as a research subject. It is not a reason to treat it as established.
In April 2026 the FDA restructured its compounding categories, and BPC-157 subsequently received a favourable PCAC vote for the 503A Bulks List. A favourable vote is not an approval — see the regulatory status section below.
Theorized — the strongest preclinical case here
Gastric ulceration and NSAID gastropathy
Pathophysiology
NSAIDs inhibit cyclo-oxygenase and with it the prostaglandins that maintain gastric mucosal defence: mucus, bicarbonate and mucosal blood flow. The resulting erosions and ulcers are among the most common serious adverse drug effects in medicine.
Mechanistic rationale
This is where BPC-157 came from. It was isolated as a fragment of a protein found in human gastric juice, and it was first characterised as a gastroprotective agent. Rodent studies report protection against NSAID-induced lesions, accelerated ulcer healing, and preserved mucosal blood flow. Of everything on this page, this is the claim whose evidence is closest to the tissue it originated in — which is the strongest thing that can be said for it, and it is still rodent data.
Community reports
Community use to tolerate an NSAID course is common and consistently reported as helpful. The obvious problem is that it treats the symptom of a drug that could be substituted or stopped.
Components carrying the argument: Gastric mucosal defence, angiogenesis, mucosal blood flow
Theorized — right organ, wrong evidence tier
Inflammatory bowel disease
Pathophysiology
Crohn disease and ulcerative colitis are immune-mediated, relapsing, and capable of causing strictures, fistulae and bowel resection while someone waits to see whether something works.
Mechanistic rationale
Rodent colitis models report reduced inflammation, improved mucosal healing and fistula closure. The tissue is right and the mechanism is coherent. What does not exist is a single controlled human trial, in a disease where the approved options — anti-TNF, anti-integrin, anti-IL-12/23 and JAK inhibitors — have mucosal healing and surgery-avoidance data behind them.
Community reports
Frequently combined with KPV in community protocols for IBD. Reports are positive and uncontrolled, and IBD relapses and remits on its own, which makes uncontrolled reporting close to uninterpretable in this disease specifically.
Components carrying the argument: Mucosal healing, anti-inflammatory signalling, angiogenesis
Theorized — the measurement is real, the syndrome is not
IBS and intestinal permeability
Pathophysiology
Intestinal permeability is measurable and genuinely altered in several conditions. "Leaky gut" as a standalone diagnosis explaining unrelated symptoms is a marketing construct built on top of that real measurement.
Mechanistic rationale
Tight-junction and barrier-integrity effects are reported in rodent models, which is the whole basis for the permeability claim. The gap is not the mechanism — it is that no controlled work links a permeability change to symptom improvement in a person. And the mechanism itself has now been tested by a purpose-built drug: larazotide acetate, an eight-residue tight-junction regulator, reached phase 3 in coeliac disease — the best-characterised barrier condition in medicine — and was discontinued in 2022 for insufficient benefit. That does not disprove anything about this compound, and it does mean the tight-junction hypothesis has had its best shot and missed.
Community reports
Among the most consistently positive categories of community reporting for this compound. It is also the category where placebo response is largest, because the endpoints are entirely subjective and fluctuating.
Components carrying the argument: Tight-junction proteins, barrier integrity
Theorized — the biggest use, not the best evidence
Tendon and ligament injury
Pathophysiology
Tendon heals slowly because it is poorly vascularised, and most chronic tendinopathy is degenerative rather than inflammatory — which is why anti-inflammatory approaches underperform in it.
Mechanistic rationale
Rodent tendon and ligament transection studies report accelerated healing and increased tendon fibroblast outgrowth, and the pro-angiogenic effect is a coherent answer to the vascularity problem. No human trial in tendinopathy exists. This is the single most common reason people buy this compound and it is not the strongest evidence on this page.
Community reports
The dominant use case in the grey market, usually as part of a Wolverine stack. Reports of faster return to training are ubiquitous and impossible to separate from natural healing, load management and the passage of time.
Components carrying the argument: Angiogenesis, fibroblast outgrowth, collagen organisation
Actionable warning
The problem with accelerating a recovery that protects you
Pathophysiology
Pain during tendon and joint healing is load information. It is the signal that limits what tissue with reduced capacity is asked to do.
Mechanistic rationale
If a compound reduces pain faster than it restores tissue capacity, it removes the brake before it fixes the engine. That is the mechanism by which a partial tear becomes a complete one. The concern applies specifically to the population most likely to use this compound: people who want to return to training sooner than they otherwise would.
Community reports
Reports of re-injury after returning to load early are present in community discussion and are usually attributed to bad luck rather than to the timeline.
Components carrying the argument: A consequence of the claimed effect, not a side effect
Theorized — with a sterility problem attached
Osteoarthritis and intra-articular use
Pathophysiology
Cartilage is avascular and aneural. Joint pain in osteoarthritis comes from subchondral bone, synovium and capsule rather than from the cartilage itself.
Mechanistic rationale
Rodent joint injury models exist and the repair rationale carries over from tendon. What does not carry over is the delivery: intra-articular injection outside a clinical setting is the highest-risk practice documented anywhere on this site. A septic joint is a surgical emergency that destroys cartilage in days, and the joint space has no meaningful immune clearance of its own.
Community reports
Intra-articular self-injection is discussed openly in community spaces. Nothing on this page is a suggestion to do it, and this entry exists to state the specific consequence rather than to leave it unsaid.
Components carrying the argument: Repair signalling; the risk is procedural, not pharmacological
Theorized — preclinical, and interesting
Traumatic brain injury and peripheral nerve injury
Pathophysiology
Both involve a primary mechanical injury followed by a secondary cascade of inflammation, oxidative stress and impaired perfusion, and it is the secondary phase that most treatment targets.
Mechanistic rationale
Rodent TBI and peripheral nerve transection models report improved functional recovery, and the proposed mechanism runs through the nitric oxide system and angiogenesis rather than anything neurone-specific. It is among the more genuinely interesting preclinical findings for this compound, and it is a long way from a person.
Community reports
Post-concussion use is discussed, particularly in combat sports communities. Concussion recovery is highly variable and largely spontaneous, which makes self-assessment here close to worthless.
Components carrying the argument: NO system, angiogenesis, growth factor expression
Theorized — grounded premise
Gut barrier and levothyroxine absorption
Pathophysiology
Levothyroxine absorption occurs mainly in the jejunum and ileum and is genuinely sensitive to gastrointestinal conditions. Coeliac disease, H. pylori gastritis, atrophic gastritis and inflammatory bowel disease all measurably increase levothyroxine requirement — and coeliac disease is substantially more common in Hashimoto than in the general population.
Mechanistic rationale
BPC-157 is proposed to restore mucosal integrity and tight-junction function, improving absorption of both levothyroxine and the trace minerals thyroid metabolism depends on. That second part has real biochemistry behind it: the deiodinases converting T4 to T3 are selenoenzymes. The premise — that malabsorption matters here — is clinically established, unlike most premises in this library.
Community reports
Users report improved gut symptoms and better tolerance of oral medication and supplements. Gut complaints are common in this population and improving them is a plausible gain independent of any thyroid effect.
Components carrying the argument: Mucosal repair, tight-junction integrity
Actionable warning
The thyroid risk nobody mentions
Pathophysiology
Levothyroxine has a narrow therapeutic index and is titrated against the absorption a person actually has. Someone with impaired absorption is by definition on a dose calibrated to that impairment.
Mechanistic rationale
If BPC-157 genuinely improves levothyroxine absorption, the existing dose becomes an overdose. The result is iatrogenic thyrotoxicosis — palpitations, tremor, anxiety, heat intolerance, and over time atrial fibrillation and bone loss. This is not an objection to the mechanism; it is the direct consequence of the mechanism working as claimed.
Community reports
Reports of feeling "wired", anxious or hot after adding gut-repair peptides are usually attributed to the peptide. In a replaced person those are also the symptoms of over-replacement, and the two are indistinguishable without a thyroid function test.
Components carrying the argument: Applies to anything improving gut absorption
Theorized — comorbidity is real, the chain is not
Fibromyalgia and the gut—brain argument
Pathophysiology
Fibromyalgia is a disorder of central pain processing. Irritable bowel syndrome is genuinely and highly comorbid with it, and gut symptoms are a substantial part of the burden many patients carry.
Mechanistic rationale
The proposal is that repairing the gut barrier reduces systemic inflammatory load and dampens gut—brain signalling that amplifies central pain. Split that into two claims. That BPC-157 might improve IBS symptoms is plausible and would be a real quality-of-life gain in a comorbid condition. That improving the gut then reduces central pain amplification is a much longer chain, and fibromyalgia is not characterised by elevated systemic inflammation for the "inflammatory load" step to reduce.
Community reports
Users with both conditions report gut improvement more consistently than pain improvement — which is what the two-claim split would predict.
Components carrying the argument: Gut barrier; the central-pain link is inferential
| Condition | Premise | Evidence | The thing to know |
|---|---|---|---|
| NSAID gastropathy / ulcer | Strong — origin tissue | Rodent | PPIs and stopping the NSAID both work |
| Inflammatory bowel disease | Sound | Rodent | Delay costs bowel — approved biologics have surgery-avoidance data |
| IBS / permeability | Partial | Rodent | Largest placebo response of anything here |
| Tendon / ligament | Sound | Rodent | Most common use, not the best evidence |
| Osteoarthritis | Weak | Rodent | Intra-articular injection risks a septic joint |
| TBI / nerve injury | Sound | Rodent | Recovery is spontaneous and variable — self-assessment fails |
| Hypothyroidism | Established | None | Improved absorption makes the existing dose an overdose |
| Fibromyalgia | Partial | None | Wrong compartment — the disorder is central |
What actually has evidence for these conditions
Gastrointestinal: proton pump inhibitors and H. pylori eradication resolve most ulcer disease, and substituting or stopping the NSAID resolves the cause. Inflammatory bowel disease has an entire pharmacological armoury with mucosal healing endpoints. For IBS: a structured low-FODMAP trial with reintroduction, soluble fibre, and gut-directed cognitive behavioural therapy or hypnotherapy, which has better evidence than most drug options. Excluding coeliac disease and IBD before accepting an IBS label matters more than any of it.
Musculoskeletal: progressive mechanical loading — heavy slow resistance or eccentric protocols sustained over months — has the best evidence in tendinopathy and outperforms every injectable it has been compared against. In knee osteoarthritis, exercise therapy and weight reduction are first-line in every guideline.
Thyroid: if malabsorption is suspected it is diagnosable — coeliac serology, H. pylori testing, a coeliac-aware dietary history. Levothyroxine timing is frequently the culprit and costs nothing to fix. If the argument is improved absorption of selenium, iron and zinc for T4 → T3 conversion, the more direct move is to measure and correct them.
Fibromyalgia has approved pharmacotherapy — pregabalin, duloxetine and milnacipran — and the intervention with the strongest evidence of any kind is graded exercise combined with cognitive behavioural therapy. Note what duloxetine and milnacipran are: serotonin–noradrenaline reuptake inhibitors. The treatments that work here act centrally. That is the yardstick any peptide rationale should be measured against.
06 Handling, reconstitution & storage
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
Reconstitution
Supplied lyophilised, most commonly 5 or 10 mg per vial. Reconstituted with bacteriostatic water; a 5 mg vial at 250 mcg/day is twenty days of use, which fits comfortably inside typical in-use windows.
Storage
Lyophilised: refrigerated or frozen, protected from light; reported as unusually stable in the lyophilised state and notably stable in human gastric juice — a property specific to this peptide and part of why oral routes are studied at all. Reconstituted: 2–8 °C.
Common vial sizes
Most commonly 5 mg and 10 mg lyophilised vials. Also supplied as an oral arginate salt.
Stability notes
The pentadecapeptide is comparatively robust, but reconstituted solution is still a sterile-handling problem first and a chemistry problem second.
07 Legal & regulatory status
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Not approved for human use anywhere. Sold as a research chemical. In the United States the FDA has placed BPC-157 in the category of substances that present significant safety risks for use in compounding, effectively excluding it from legitimate compounding pharmacy supply. It is not an approved drug, not a dietary-supplement-eligible ingredient, and not GMP-manufactured unless a specific supplier documents otherwise.
Regulatory update — current as at August 2026
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for inclusion on the Section 503A Bulks List (8–6, one abstention). It was one of six peptides recommended — alongside BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — out of seven considered.
This followed the FDA's announcement of 15 April 2026 removing twelve peptides from Category 2, the designation for substances judged to raise significant safety concerns. That removal stripped away the basis for enforcement against compounders but did not itself authorise anything, leaving these compounds in a regulatory grey area pending the PCAC review.
A PCAC recommendation is not an approval, and the 503A Bulks List is not a drug approval either. It is also worth knowing that July 2026 was the second round: across two sittings in October and December 2024 the same committee reviewed seven substances — among them ipamorelin, kisspeptin-10, AOD-9604, CJC-1295 and thymosin alpha-1 — and rejected all seven. Two separate things are being conflated in almost every write-up of the 2026 decision:
- The vote is advisory. PCAC recommendations are non-binding. The pathway from here runs: removal from Category 2 (done, April 2026) → PCAC recommendation (done, July 2026) → placement in Category 1 through notice-and-comment rulemaking, which commonly takes eight to twelve months → and the HHS Secretary must sign off on any addition to the list. Nothing is lawfully compoundable on the strength of the vote alone.
- Even a successful listing would not make these approved drugs. Inclusion on the 503A Bulks List permits a licensed compounding pharmacy to use the substance in a compounded preparation for an individual patient with a prescription. It says nothing about the compound being demonstrated safe and effective — no efficacy trial is required, and none of these has one.
- It would not legitimise research-chemical supply. A compounding pathway runs through a licensed pharmacy and a prescriber. Grey-market vials labelled "research use only" are not that, and nothing in this decision changes their status.
Regulatory and trial claims re-checked against primary sources on 18 August 2026. Checked: PCAC vote 23-24 July 2026 and the 503A pathway; the PL 14736 phase 1 and phase 2 clinical history; the systemic distant-organ rodent literature (ischaemia-reperfusion, SMA occlusion, per-oral muscle-to-bone) and the absence of any tachyphylaxis study. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Anti-doping
BPC-157 is explicitly named on the WADA Prohibited List under S0 (non-approved substances). It is prohibited at all times, in and out of competition, for any athlete subject to WADA-code testing.
§ Sources & further reading
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–32.Review or meta-analysis
- Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. (and related reviews)Review or meta-analysis
- PubMed: BPC 157 / PL 14736 — complete indexed literature (live query)Database or literature search
- Sikirić P, et al. Stable gastric pentadecapeptide BPC 157 – NO-system relation. Curr Pharm Des. 2014.Review or meta-analysis
- Sikirić P, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021.Review or meta-analysis
- PubMed: BPC 157 muscle, tendon and nerve healing models (live query)Database or literature search
- Protective Effects of BPC 157 on Liver, Kidney and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury. 2025.Pre-clinical / animal study
- Sikirić P, et al. Occlusion of the Superior Mesenteric Artery in Rats Reversed by Collateral Pathways Activation: BPC 157 Counteracts Multiple Organ Dysfunction Syndrome. 2021.Pre-clinical / animal study
- BPC 157 Therapy After Surgical Detachment of the Quadriceps Muscle for Muscle-to-Bone Reattachment in Rats — per-oral dosing. 2025.Pre-clinical / animal study
- US FDA — bulk drug substances nominated for compounding: category 2 (significant safety risk) listingRegulatory / official document
- WADA Prohibited List (current edition) — S0 non-approved substancesRegulatory / official document
Reminder
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.